Literature DB >> 35713866

A Hybrid Protocol for Identifying Comorbidity-Based Potential Drugs for COVID-19 Using Biomedical Literature Mining, Network Analysis, and Deep Learning.

Archana Prabahar1, Anbumathi Palanisamy2.   

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has spread on an unprecedented scale around the globe. Despite of 141,975 published papers on COVID-19 and several hundreds of new studies carried out every day, this pandemic remains as a global challenge. Biomedical literature mining helps the researchers to understand the etiology of the disease and to gain an in-depth knowledge of the disease, potential drugs, vaccines developed and novel therapies. In addition to the available treatments, there is a huge need to address the comorbidity-based disease mortality in case of COVID-19 patients with type 2 diabetes mellitus (T2D), hypertension and cardiovascular disease (CVD). In this chapter, we provide a hybrid protocol based on biomedical literature mining, network analysis of omics data, and deep learning for the identification of most potential drugs for COVID-19.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  COVID-19; Comorbidity; Deep learning; Drug repurposing; Literature mining; Network analysis

Mesh:

Substances:

Year:  2022        PMID: 35713866     DOI: 10.1007/978-1-0716-2305-3_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  40 in total

1.  Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.

Authors:  Denisa Bojkova; Kevin Klann; Benjamin Koch; Marek Widera; David Krause; Sandra Ciesek; Jindrich Cinatl; Christian Münch
Journal:  Nature       Date:  2020-05-14       Impact factor: 69.504

2.  COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.

Authors:  Alexander V Sorokin; Sotirios K Karathanasis; Zhi-Hong Yang; Lita Freeman; Kazuhiko Kotani; Alan T Remaley
Journal:  FASEB J       Date:  2020-06-26       Impact factor: 5.191

Review 3.  Coronaviruses - drug discovery and therapeutic options.

Authors:  Alimuddin Zumla; Jasper F W Chan; Esam I Azhar; David S C Hui; Kwok-Yung Yuen
Journal:  Nat Rev Drug Discov       Date:  2016-02-12       Impact factor: 84.694

4.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.

Authors:  Peter Richardson; Ivan Griffin; Catherine Tucker; Dan Smith; Olly Oechsle; Anne Phelan; Michael Rawling; Edward Savory; Justin Stebbing
Journal:  Lancet       Date:  2020-02-04       Impact factor: 79.321

Review 5.  COVID-19 and the human innate immune system.

Authors:  Joachim L Schultze; Anna C Aschenbrenner
Journal:  Cell       Date:  2021-02-16       Impact factor: 41.582

6.  COVID-19: combining antiviral and anti-inflammatory treatments.

Authors:  Justin Stebbing; Anne Phelan; Ivan Griffin; Catherine Tucker; Olly Oechsle; Dan Smith; Peter Richardson
Journal:  Lancet Infect Dis       Date:  2020-02-27       Impact factor: 25.071

7.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

8.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Authors:  Daniel Blanco-Melo; Benjamin E Nilsson-Payant; Wen-Chun Liu; Skyler Uhl; Daisy Hoagland; Rasmus Møller; Tristan X Jordan; Kohei Oishi; Maryline Panis; David Sachs; Taia T Wang; Robert E Schwartz; Jean K Lim; Randy A Albrecht; Benjamin R tenOever
Journal:  Cell       Date:  2020-05-15       Impact factor: 41.582

9.  Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.

Authors:  Andre C Kalil; Thomas F Patterson; Aneesh K Mehta; Kay M Tomashek; Cameron R Wolfe; Varduhi Ghazaryan; Vincent C Marconi; Guillermo M Ruiz-Palacios; Lanny Hsieh; Susan Kline; Victor Tapson; Nicole M Iovine; Mamta K Jain; Daniel A Sweeney; Hana M El Sahly; Angela R Branche; Justino Regalado Pineda; David C Lye; Uriel Sandkovsky; Anne F Luetkemeyer; Stuart H Cohen; Robert W Finberg; Patrick E H Jackson; Babafemi Taiwo; Catharine I Paules; Henry Arguinchona; Nathaniel Erdmann; Neera Ahuja; Maria Frank; Myoung-Don Oh; Eu-Suk Kim; Seow Y Tan; Richard A Mularski; Henrik Nielsen; Philip O Ponce; Barbara S Taylor; LuAnn Larson; Nadine G Rouphael; Youssef Saklawi; Valeria D Cantos; Emily R Ko; John J Engemann; Alpesh N Amin; Miki Watanabe; Joanne Billings; Marie-Carmelle Elie; Richard T Davey; Timothy H Burgess; Jennifer Ferreira; Michelle Green; Mat Makowski; Anabela Cardoso; Stephanie de Bono; Tyler Bonnett; Michael Proschan; Gregory A Deye; Walla Dempsey; Seema U Nayak; Lori E Dodd; John H Beigel
Journal:  N Engl J Med       Date:  2020-12-11       Impact factor: 176.079

10.  A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

Authors:  David E Gordon; Gwendolyn M Jang; Mehdi Bouhaddou; Jiewei Xu; Kirsten Obernier; Kris M White; Matthew J O'Meara; Veronica V Rezelj; Jeffrey Z Guo; Danielle L Swaney; Tia A Tummino; Ruth Hüttenhain; Robyn M Kaake; Alicia L Richards; Beril Tutuncuoglu; Helene Foussard; Jyoti Batra; Kelsey Haas; Maya Modak; Minkyu Kim; Paige Haas; Benjamin J Polacco; Hannes Braberg; Jacqueline M Fabius; Manon Eckhardt; Margaret Soucheray; Melanie J Bennett; Merve Cakir; Michael J McGregor; Qiongyu Li; Bjoern Meyer; Ferdinand Roesch; Thomas Vallet; Alice Mac Kain; Lisa Miorin; Elena Moreno; Zun Zar Chi Naing; Yuan Zhou; Shiming Peng; Ying Shi; Ziyang Zhang; Wenqi Shen; Ilsa T Kirby; James E Melnyk; John S Chorba; Kevin Lou; Shizhong A Dai; Inigo Barrio-Hernandez; Danish Memon; Claudia Hernandez-Armenta; Jiankun Lyu; Christopher J P Mathy; Tina Perica; Kala Bharath Pilla; Sai J Ganesan; Daniel J Saltzberg; Ramachandran Rakesh; Xi Liu; Sara B Rosenthal; Lorenzo Calviello; Srivats Venkataramanan; Jose Liboy-Lugo; Yizhu Lin; Xi-Ping Huang; YongFeng Liu; Stephanie A Wankowicz; Markus Bohn; Maliheh Safari; Fatima S Ugur; Cassandra Koh; Nastaran Sadat Savar; Quang Dinh Tran; Djoshkun Shengjuler; Sabrina J Fletcher; Michael C O'Neal; Yiming Cai; Jason C J Chang; David J Broadhurst; Saker Klippsten; Phillip P Sharp; Nicole A Wenzell; Duygu Kuzuoglu-Ozturk; Hao-Yuan Wang; Raphael Trenker; Janet M Young; Devin A Cavero; Joseph Hiatt; Theodore L Roth; Ujjwal Rathore; Advait Subramanian; Julia Noack; Mathieu Hubert; Robert M Stroud; Alan D Frankel; Oren S Rosenberg; Kliment A Verba; David A Agard; Melanie Ott; Michael Emerman; Natalia Jura; Mark von Zastrow; Eric Verdin; Alan Ashworth; Olivier Schwartz; Christophe d'Enfert; Shaeri Mukherjee; Matt Jacobson; Harmit S Malik; Danica G Fujimori; Trey Ideker; Charles S Craik; Stephen N Floor; James S Fraser; John D Gross; Andrej Sali; Bryan L Roth; Davide Ruggero; Jack Taunton; Tanja Kortemme; Pedro Beltrao; Marco Vignuzzi; Adolfo García-Sastre; Kevan M Shokat; Brian K Shoichet; Nevan J Krogan
Journal:  Nature       Date:  2020-04-30       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.